Understanding the unique attributes of muc16 (ca125): potential implications in targeted therapy

Cancer Research

Volumn 75, Issue 22, 2015, Pages 4669-4674

  Das, Srustidhar ^a   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HN125; MONOCLONAL ANTIBODY MUC16; TUMOR MARKER; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

CANCER CELL; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; ANIMAL; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; TRENDS;

ANIMALS; CA-125 ANTIGEN; HUMANS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84955470463     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1050     Document Type: Review

References (41)

1. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22:348-66.
2. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 gene: A newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002;23:154-69.
3. Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 2002;98:737-40.
4. Govindarajan B, Gipson IK. Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res 2010;90:655-63.
5. Marcos-Silva L, Narimatsu Y, Halim A, Campos D, Yang Z, Tarp MA, et al. Characterization of binding epitopes of CA125 monoclonal antibodies. J Proteome Res 2014;13:3349-59.
6. Macao B, Johansson DG, Hansson GC, Hard T. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol 2006;13:71-6.
7. Fendrick JL, Konishi I, Geary SM, Parmley TH, Quirk JG Jr, O'Brien TJ. CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Tumour Biol 1997;18:278-89.
8. Konishi I, Fendrick JL, Parmley TH, Quirk JG Jr, O'Brien TJ. Epidermal growth factor enhances secretion of the ovarian tumor-associated cancerantigen CA125 from the human amnion WISH cell line. J Soc Gynecol Investig 1994;1:89-96.
9. Goodell CA, Belisle JA, Gubbels JA, Migneault M, Rancourt C, Connor J, et al. Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of crossreactive monoclonal antibodies. J Ovarian Res 2009;2:8.
10. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
11. Das S, Majhi PD, Al-Mugotir MH, Rachagani S, Sorgen P, Batra SK. Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying golgi/post-golgi compartments. Sci Rep 2015;5:9759.
12. Seelenmeyer C, Wegehingel S, Lechner J, Nickel W. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci 2003;116:1305-18.
13. Xiong L, Woodward AM, Argueso P. Notch signaling modulates MUC16 biosynthesis in an in vitro model of human corneal and conjunctival epithelial cell differentiation. Invest Ophthalmol Vis Sci 2011;52:5641-6.
14. Seo KY, Chung SH, Lee JH, Park MY, Kim EK. Regulation of membraneassociated mucins in the human corneal epithelial cells by dexamethasone. Cornea 2007;26:709-14.
15. Das S, Rachagani S, Torres-Gonzalez MP, Lakshmanan I, Majhi PD, Smith LM, et al. Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget 2015;6:5772-87.
16. Haridas D, Chakraborty S, Ponnusamy MP, Lakshmanan I, Rachagani S, Cruz E, et al. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS ONE 2011;6:e26839.
17. Haridas D, Ponnusamy MP, Chugh S, Lakshmanan I, Seshacharyulu P, Batra SK. MUC16: Molecular analysis and its functional implications in benign and malignant conditions. FASEB J 2014;28:4183-99.
18. Boivin M, Lane D, Piche A, Rancourt C. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol 2009;115:407-13.
19. Matte I, Lane D, Boivin M, Rancourt C, Piche A. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer 2014;14:234.
20. Akita K, Tanaka M, Tanida S, Mori Y, Toda M, Nakada H. CA125/MUC16 interacts with src family kinases, and over-expression of its C-terminal fragment in human epithelial cancer cells reduces cell-cell adhesion. Eur J Cell Biol 2013;92:257-63.
21. Giannakouros P, Matte I, Rancourt C, Piche A. Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail. Int J Oncol 2015;46:91-8.
22. Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, et al. CA125/MUC16 is dispensable for mouse development and reproduction. PLoS ONE 2009;4:e4675.
23. Mai PL, Wentzensen N, Greene MH. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res 2011;4:303-6.
24. Kim N, Hong Y, Kwon D, Yoon S. Somatic mutaome profile in human cancer tissues. Genomics Inform 2013;11:239-44.
25. Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, Konstantopoulos K, et al. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol 2012;43:1755-63.
26. Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci 2012;103: 739-46.
27. Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 2011;121:434-43.
28. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004;22:3507-16.
29. Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of theAGOOVAR, COGI, GINECO, andGEICO-the MIMOSA study. J Clin Oncol 2013;31:1554-61.
30. Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, et al. MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress. Mol Cancer 2014;13:129.
31. Dharma Rao T, Park KJ, Smith-Jones P, Iasonos A, Linkov I, Soslow RA, et al. Novel monoclonal antibodies against the proximal (carboxyterminal) portions of MUC16. Appl Immunohistochem Mol Morphol 2010;18:462-72.
32. Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR, et al. Successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res 2010;16:3594-606.
33. Carew JS, Nawrocki ST, Krupnik YV, Dunner K Jr, McConkey DJ, Keating MJ, et al. Targeting endoplasmic reticulum protein transport: A novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 2006;107:222-31.
34. Argueso P, Guzman-Aranguez A, Mantelli F, Cao Z, Ricciuto J, Panjwani N. Association of cell surfacemucins with galectin-3 contributes to the ocular surface epithelial barrier. J Biol Chem 2009;284:23037-45.
35. Belisle JA, Horibata S, Jennifer GA, Petrie S, Kapur A, Andre S, et al. Identification of siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 2010;9:118.
36. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5:50.
37. Chen SH, Dallas MR, Balzer EM, Konstantopoulos K. Mucin 16 is a functional selectin ligand on pancreatic cancer cells. FASEB J 2012;26: 1349-59.
38. Blalock TD, Spurr-Michaud SJ, Tisdale AS, Heimer SR, GilmoreMS, Ramesh V, et al. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci 2007;48:4509-18.
39. Lakshmanan I, Ponnusamy MP, Das S, Chakraborty S, Haridas D, Mukhopadhyay P, et al. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 2012;31:805-17.
40. Garg G, Gibbs J, Belt B, Powell MA, Mutch DG, Goedegebuure P, et al. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein meso-TR3. BMC Cancer 2014; 14:35.
41. Xiang X, Feng M, Felder M, Connor JP, Man YG, Patankar MS, et al. HN125: A novel immunoadhesin targeting MUC16 with potential for cancer therapy. J Cancer 2011;2:280-91.